SML2868
Aclidinium bromide
≥98% (HPLC)
别名:
(3R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide, (3R)-3-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide
SMILES string
[s]1c(ccc1)C(O)(c5[s]ccc5)C(=O)O[C@@H]2C3CC[N+](C2)(CC3)CCCOc4ccccc4.[Br-]
InChI
1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1
InChI key
XLAKJQPTOJHYDR-QTQXQZBYSA-M
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -24 to -30°, c = 0.1 in methanol
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) bronchodilator. It is a muscarinic M3, M2 antagonist with a long residence time at M3 receptors and a shorter residence time at M2 receptors. Aclidinium bromide was approved for the treatment of chronic obstructive pulmonary disease (COPD) in July 2012.
Long-acting muscarinic receptor antagonist; Bronchodilator.
存储类别
11 - Combustible Solids
wgk
WGK 3
法规信息
新产品
此项目有
Amadeu Gavaldà et al.
The Journal of pharmacology and experimental therapeutics, 331(2), 740-751 (2009-08-28)
Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease. Aclidinium showed subnanomolar affinity for the five human muscarinic receptors (M(1)-M(5)). [(3)H]Aclidinium dissociated slightly faster from M(2) and M(3) receptors
François Maltais et al.
Therapeutic advances in respiratory disease, 6(6), 345-361 (2012-10-19)
Long-acting muscarinic antagonists (LAMAs) play a central role in the management of chronic obstructive pulmonary disease (COPD). Previously, only one LAMA (tiotropium) was available for the treatment of COPD, necessitating the development of other therapeutic options due to the heterogeneity
Z-Z Li et al.
European review for medical and pharmacological sciences, 23(1), 105-112 (2019-01-19)
Osteosarcoma is recognized as the most common primary malignant bone tumor, the 5-year disease-free survival rate in patients with metastatic or recurrent disease is below than 30%. Drug resistance and toxic side effects limit the therapeutic efficacy of osteosarcoma. Therefore
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持